Showing 3641-3650 of 7034 results for "".
- Daily Imaging Boosts NMSC Treatment Success: Analysishttps://practicaldermatology.com/news/daily-imaging-boosts-nmsc-treatment-success-analysis/2468003/Image-guided superficial radiation therapy (IGSRT) was associated with a 99% cure rate for non-melanoma skin cancer (NMSC) when delivered with daily imaging, which allows for adaptive changes based on tumor depth fluctuations. Researchers for a recent retrospective study looked at the rol
- Dupilumab Reduces Inflammatory Biomarkers in Pediatric AD: Studyhttps://practicaldermatology.com/news/dupilumab-reduces-inflammatory-biomarkers-pediatric-ad/2467953/Dupilumab significantly reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis (AD), according to results from recent phase 3 trials. Pediatric patients treated with dupilumab demonstrated substantial reductions in key serum biomarkers associated w
- European Commission Approves Celltrion’s Stelara Biosimilar SteQeymahttps://practicaldermatology.com/news/european-commission-approves-celltrions-stelara-biosimilar-steqeyma/2467952/Celltrion announced that the European Commission (EC) has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases, including psoriasis. The EC's approval follows a positive opinion from the Committee for Medici
- Higher BMI in Early Childhood Linked with Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/higher-bmi-early-childhood-linked-increased-atopic-dermatitis-risk/2467912/New research indicates that a higher body mass index (BMI) in early childhood is associated with an increased risk of developing immune-mediated skin diseases (IMSDs) such as atopic dermatitis (AD), alopecia areata (AA), and psoriasis. The research team looked at data on over 2 million chi
- Genome-Wide Study Reveals Genetic Correlation Between Melanoma Subtypeshttps://practicaldermatology.com/news/genome-wide-study-reveals-genetic-correlation-between-melanoma-subtypes/2467851/Data from a recent genome-wide association study (GWAS) looking at the genetic underpinnings of in situ and invasive melanoma show significant shared genetic architecture between the two. Researchers for the study used data from four population-based genetic cohorts, including the UK Bio
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- Study: Vegan Nutraceutical Improves Hair Health in Plant-Based Dietershttps://practicaldermatology.com/news/study-vegan-nutraceutical-improves-hair-health-plant-based-dieters/2467690/A recent clinical study suggested that a novel vegan nutraceutical supported hair health in women following plant-based diets. Seeking to address the nutrient deficiencies that can affect hair growth and quality in this population, researchers for the single-blind prospective study conduc
- FDA Issues Warning to Matte Beauty Over Unapproved Chemical Peelshttps://practicaldermatology.com/news/fda-issues-warning-matte-beauty-over-unapproved-chemical-peels/2467661/The U.S. Food and Drug Administration (FDA) recently sent a warning letter to Matte Beauty, addressing what the agency described as significant regulatory violations regarding their chemical peel products. According to the July 25 letter, the products in question include “TCA 100% Skin Pe
- New Algorithm Helps Detect Aggressive Basal Cell Carcinoma for Optimal Treatmenthttps://practicaldermatology.com/news/new-algorithm-helps-detect-aggressive-basal-cell-carcinoma-optimal-treatment/2467648/An algorithm can help healthcare professionals recognize which patients have a highly aggressive form of basal cell carcinoma (BCC) of the face. These are the findings of a study conducted at the University of Gothenburg. If more BCCs are correctly identified as high-risk, the patients can direct
- sNDA Submitted for Roflumilast Foam 0.3% for Scalp and Body Psoriasishttps://practicaldermatology.com/news/snda-submitted-roflumilast-foam-03-scalp-and-body-psoriasis/2467457/A supplemental New Drug Application (sNDA) has been submitted for ZORYVE (roflumilast) foam 0.3%, a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis, Arcutis Biotherapeutics, Inc., announce